Beam Therapeutics Eyes Its First Drug Filing By Year-End As Quarterly Loss Widens To $134.4 Million
The gene-editing company says cash plus a $200 million credit draw lasts into mid-2029, with cash at $1.0 billion.
Beam Therapeutics, which develops gene-editing medicines built on base editing, said it could file its first biologics license application, for sickle cell therapy risto-cel, as early as year-end 2026, while its third-quarter net loss widened to $134.4 million, or $1.28 per share. The company reported the results Tuesday in an 8-K; a year earlier the loss was $112.6 million, or $1.10 per share.
Revenue dried up, spending held
License and collaboration revenue fell to $307 thousand from $9.7 million a year earlier. Total operating expenses rose to $141.6 million from $136.5 million.
General and administrative costs climbed to $31.5 million from $26.7 million. Research and development was nearly flat at $110.1 million, against $109.8 million.
For the first nine months, the net loss was $351.4 million, or $3.38 per share, compared with $323.0 million, or $3.31 per share, in the same period of 2025.
Cash into mid-2029
Cash, cash equivalents and marketable securities stood at $1.0 billion on September 30, down from $1.2 billion at the end of 2025. Beam expects that cash, plus an additional $200 million it expects to draw from its Sixth Street credit facility, to fund operations into mid-2029, assuming the conditions on those borrowings are met.
The company says that runway should carry it through a potential risto-cel launch, the pivotal plan for BEAM-302 and clinical proof of concept for BEAM-304.
Four programs, one near a filing
Beam's lead programs include risto-cel, an investigational sickle cell therapy, and BEAM-302, a one-time treatment for alpha-1 antitrypsin deficiency, an inherited lung and liver disorder. It earns money through collaborations with drug companies including Pfizer, Apellis and Eli Lilly.
Beam expects to report updated risto-cel data by year-end 2026. CEO John Evans said the company is "approaching a potential first BLA filing with risto-cel as early as the end of this year."
Dosing in the BEAM-302 pivotal cohort is expected to finish in the first half of 2027. In September, Beam presented data with up to 18 months of follow-up showing durable increases in functional AAT, the protein the disease leaves deficient.
Beam also presented early data for BEAM-301, aimed at glycogen storage disease type Ia; two of three patients in the 40 mg cohort reached the protocol's maximum controlled fasting time of at least 15 hours. A 60 mg cohort is enrolling. Dosing in the BEAM-304 phenylketonuria trial is expected to start in early 2027.
In September, Beam named Eric Foster chief commercial officer.
Beam's management next appears in a fireside chat at the Guggenheim healthcare conference in Boston on Tuesday, November 10, at 9:00 a.m. ET.
Sources
- 8-K Filing — Beam Therapeutics Inc. (BEAM) — SEC EDGAR
- Exhibit beam-ex99_1.htm — Beam Therapeutics Inc. 8-K exhibit — SEC EDGAR
- Why Beam Therapeutics Stock Is Up 15.6% And What's Next — Yahoo Finance
- Beam Therapeutics Reports Third Quarter 2026 Financial — globenewswire.com